AzTrials
AzTrials

Perceptual DisordersSmart traceNCT04573413

Repetitive Transcranial Magnetic Stimulation in Traumatic Brain Injury

A study testing Inhibitory repetitive transcranial magnetic stimulation in people with Perceptual Disorders and Traumatic Brain Injury, run by Azienda Usl di Bologna at 1 site in Italy.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Randomized Controlled Trial (RCT) aiming at assessing the efficacy of a novel rehabilitation protocol, based on repetitive transcranial magnetic stimulation (r- TMS) in combination with a conventional cognitive treatment (CCT). Read more about this study

Who is it for?
Ages 18 to 80 years
Conditions the study is for
Perceptual Disorders, Traumatic Brain Injury
What is being tested?
Inhibitory repetitive transcranial magnetic stimulation
Type of treatment
Medical device
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
28 participants
Where
1 siteItaly
Study dates
30 Mar 2021to 30 Mar 2023
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Diagnosis of TBI;
  • Diagnosis of LHSN with specific assessment tests (line bisection test and / or star cancellation test);
  • Intra-hospital rehabilitation setting (ordinary hospitalization or DH);
  • Age between 18 and 80 years;
  • Time after injury between three weeks and 1 year;
  • Level of cognitive functioning (LCF ≥5 )
  • Adequate language comprehension

Who cannot join

  • Clinical instability at enrollment (for example, fever, acute internist conditions, etc.);
  • Presence of epileptogenic alterations to the EEG and / or previous epileptic seizures;
  • Presence of intracranial implants of metallic material;
  • Presence of devices that could be altered by rTMS, such as pacemakers, ventriculo-peritoneal derivations, Baclofen pump;
  • Acute neurosurgery, including decompressive craniotomy;
  • Drugs conditioning the state of consciousness-vigilance such as benzodiazepines;
Show all 10Show fewer
  • Cortical blindness and / or visual agnosia;
  • Concomitant psychiatric disorders and / or history of substance abuse;
  • Post-traumatic agitation
  • Post-traumatic complications (i.e. hydrocephalus)

Trial locations and contacts

1 site in 1 country.

Francesco Di Gregorio, PhD contact

3290762585

francesco.digregorio@ausl.bologna.it

Italy1 site, 1 recruiting
  • Azienda Unità Sanitaria Locale di Bologna 40124, Bologna, Italy

    Bologna, 40124

    Francesco Di Gregorio, PhD, 3290762585, francesco.digregorio@ausl.bologna.it

    Francesco Di Gregorio, Di Gregorio

    Recruiting

Other trials in Italy

About this study

Official title: Efficacy of Repetitive Transcranial Magnetic Stimulation (r-TMS) Combined With Visual Scanning Treatment on Cognitive-behavioral Symptoms of Unilateral Spatial Neglect in Patients With Traumatic Brain Injury: a Randomized Clinical Trial

Randomized Controlled Trial (RCT) aiming at assessing the efficacy of a novel rehabilitation protocol, based on repetitive transcranial magnetic stimulation (r- TMS) in combination with a conventional cognitive treatment (CCT). The protocol will be statistically compared to the same CTT administered without the r-TMS in a sample of traumatic brain injury patients (age between 18 and 80 years) with left hemispatial Neglect.

Read the detailed description

BACKGROUND: A frequent and disabling impairment in persons who suffered traumatic brain injury (TBI) is left hemi-spatial neglect (LHSN). LHSN is a spatial attentive syndrome, characterized by a reduced ability to attend, perceive and consciously represent the left contra-lesional space, in the absence of a primary sensory deficit. Persons with LHSN fail to attend any stimulus coming from the left space and this can affect the ability to carry out many everyday tasks, such as walking, eating, reading and getting dressed. Those patients, as a direct consequence of the brain injury and LHSN, are also often affected by anosognosia for hemiplegia and for LHSN, which is the lack of awareness about motor and cognitive deficits. This condition hinders motor and cognitive recovery, predisposes to falls and reduces independence. Furthermore, in TBI LHSN is often associated with a mixture of attention, memory, executive function, and processing speed deficits leading to complex cognitive and behavioral pictures, which may even interfere with the administration of standard cognitive treatments for LHSN (i.e. visual scanning protocols or prism adaptation). It is also known that 1 Hz inhibitory repetitive Transcranial Magnetic Stimulation (rTMS), applied for two weeks to the posterior parietal cortex (PPC) of the unaffected hemisphere in patients with LHSN due to ischemic lesion of the right hemisphere, induces a significant improvement of visual-spatial symptoms that persists 15 days after rTMS treatment. These results can be explained considering that spatial attention deficit in LHSN due to a right middle cerebral artery territory stroke relates to abnormal activation of neural system that mediates spatial attentive operations in the healthy brain. In LHSN, a lesion of the right PPC and of the inter-hemispheric connectivity causes an imbalance in interhemispheric activity due to hyperactivity of the left hemisphere which, in turn, causes a biased attentive allocation towards ipsilesional space. As a consequence, an inhibition of this hyperactivity may have a rebalancing effect, reducing left spatial attention deficit in LHSN. Indeed, recent studies in stroke showed also the possibility of improving the efficacy of standard cognitive treatments (i.e. visual scanning) if the latter are preceded by inhibitory rTMS on the unaffected hemisphere. What is not known is whether also in LHSN due to TBI, inhibitory rTMS on the left PPC followed by a visual scanning protocol may be an effective treatment as in right hemisphere stroke, considering that in TBI the damage is often more widespread and multifocal than in the former condition.

AIMS:

  • To compare the efficacy of a combined r-TMS and CCT intervention aiming at reducing cognitive symptoms of LHSN, in a sample of TBI patients with LHSN, within the context of an RCT.
  • To evaluate the long- term impact of the intervention and evaluate the effect of the intervention on several clinical measures (activity of daily living, attentive and motor functions) and on psychophysiological indices

METHODS: Randomized controller trial, with blind assessments on pretest, postest and on 3 months follow-up.

POPULATION: TBI patients with clinical evidence of LHSN. INTERVENTION: Inhibitory low-frequency r-TMS on the left parietal cortex combined with a conventional cognitive treatment (visual scanning training) for 2 weeks.

CONTROL: SHAM group with a placebo r-TMS stimulation combined with visual scanning training for 2 weeks.

OUTCOMES: Multidisciplinary assessment with clinical and psychophysiological indices. The primary endpoint is a psychophysiological index based on Visual-Evoked Potentials (VEPs). In particular we will focus on the N1 component, a posterior negativity, which is altered in terms of latency and amplitude in LHSN population. In order to study effects of the r-TMS in the interhemispheric parietal pathway, we will extract indices of interhemispheric transmission time (IHTT) on the N1 latency and of spatial attention bias on N1 amplitude (VABI). The secondary outcomes will consider the impact of the intervention on other clinical measures of cognitive and motor impairment and on test of activity of daily living.

EXPECTED RESULTS: The main expected outcome of the present project will provide evidence, on a large simple of TBI patients, of the interhemispheric functionality underlying cognitive symptoms of LHSN. It will point out the specific effect of rTMS protocols on the inter-hemispheric imbalance. More in details, we expect to observe in the rTMS group a larger rebalancing effect than in the control group, as demonstrated by psychophysiological indexes, with the persistence of effects at follow-up. Additionally, we expect to observe larger improvements in cognitive and behavioral symptoms of LHSN induced by the rTMS in comparison to the control group, as demonstrated by better performances on clinical tests and batteries.

RANDOMIZATION: In order to ensure that each arm will contain an equal number of individuals, eligible subjects will be randomly assigned to one of the two groups with a blocked randomization method based on a block size of 4.

ASSESSOR AND PATIENT BLINDNESS: In order to ensure a double-blind assessment, pre-treatment assessments will be performed prior to randomization. An assessor not aware of the patient randomization group will conduct post-treatment and follow-up assessments. Also the visual scanning protocol will be administered by therapists unaware of the patient randomization and patients themselves will be instructed not to reveal any information on the brain stimulation treatment received.

CASE REPORT AND DATA MONITORING: Specific case report forms (CRF) for every test in the assessments are already available and will be used. During the treatment the responsible physician will report any adverse event in the treatment-CRF. All information and results will be promptly reported on the electronic database. A researcher will be responsible for the electronic database, data analyses and will draft the single patient record at the end of all procedures. In case of lost to follow-up, the information available up to that moment will be considered. If participant is lost at follow-up, it will be analyzed on the basis of the "intention to treat" principle. Finally, the reason for quit the study will be reported for each participant lost at follow-up.

SAMPLE SIZE: The sample size was calculated using the following formula:

https://www.dropbox.com/s/y56umrt7z93en1w/Simple%20size%20formula.docx? dl=0 The sample size resulting from the formula calculated for the VABI is 24. Consequently, the minimum sufficient sample to reach the primary aim is, assuming approximately 10% of subjects lost to follow-up, 28 subjects (14 X group) recruited over a three-year period.

DATA ANALYSES: Analysis of covariance will be performed for each measure using a mixed-model ANCOVA with a 2X3 design, where the "between" factor is represented by the randomization groups (rTMS, SHAM) and the "within" factor is the assessment time (T0, T1, T2). Data analysis will be performed using Matlab and SPSS softwares.

Being tested
Inhibitory repetitive transcranial magnetic stimulation, Sham Group
Keywords
Electroenephalography, repetitive Transcranial magnetic stimulation, Hemispatial Neglect
Medical subject headings
Perceptual Disorders, Brain Injuries, Traumatic

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Inhibitory repetitive transcranial magnetic stimulationDevice

    r-TMS Parameters: International 10/20 system for the location of the target area (left parietal cortex) 60% Power Frequency: 1 Hz 90 pulse trains with 10 pulses each (total 900 stimuli), resulted in a total stimulation period of 15 minutes.

    Visual Scanning Visual-spatial training; Reading and copying training; Copying of line drawings on a dot matrix. Barrage

  • Sham GroupDevice

    Sham stimulation and Visual scanning training Intervention: Device: SHAM

Study groups in NCT04573413
Study groupRoleWhat they receive
r-TMS groupExperimentalThe interventions have a total administration time of 75 minutes per day. For rTMS stimulation, the coil will be positioned tangentially on the target area. Each rTMS session will last 15 minutes and will be administered every other day (e.g. Monday-Wednesday-Friday, Monday-Wednesday-Friday, Monday). The CCT (i.e. visual scanning treatment) involves the presence of a therapist, who administers various visual scanning tasks, used to increase patient's awareness and to teach strategies to improve spatial exploration abilities.Trainings include three increasing levels of difficulty (9 possible combinations). Each level of difficulty will be exercised until the patient reaches a level of accuracy of 75%. The CCT will be carried out in 50 minutes sessions for 5 days a week within 15 days (11 sessions in total). On the days when the rTMS is also administered, the administration of the CCT will immediately follow the brain stimulation.
Receives: Device: Inhibitory repetitive transcranial magnetic stimulation
SHAM groupSham comparatorSHAM Stimulation and Visual Scanning training. In the control group, the coil of the r-TMS will be positioned at 90° on the target area, thus no specific cortical modulation will be implemented (SHAM stimulation). For the SHAM group, the CCT protocol will be administered with the same modalities and time frame as detailed for the experimental group.
Receives: Device: Sham Group

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. visual-Attention Bias Index (vABI)

    Change from Baseline: visual-Attention Bias Index (vABI). Psychophysiological index of inter-hemispheric imbalance in a visual-spatial attention task

    Measured: up to 21 days post baseline and up to 90 days follow-up

Secondary outcomes (8)
  1. behavioral Inattention Test (BIT)

    1. Change from Baseline: behavioral Inattention Test (BIT). A battery for the assessment of cognitive and behavioral symptoms in LHSN

    Measured: up to 21 days post baseline and up to 90 days follow-up

  2. catherine Bergegò Scale (CBS)

    1. Change from Baseline: catherine Bergegò Scale (CBS). A battery for the assessment of LHSN symptoms in the activity of daily living.

    Measured: up to 21 days post baseline and up to 90 days follow-up

  3. test of Attention Performance (TAP/TEA)

    1. Change from Baseline: test of Attention Performance (TAP/TEA). Two subtest will be executed "alertness" and "Visual field/Neglect" to assess attentive functions

    Measured: up to 21 days post baseline and up to 90 days follow-up

  4. functional independence measure (FIM)

    1. Change from Baseline: functional independence measure (FIM). The motor subscale will be executed to assess motor independence

    Measured: up to 21 days post baseline and up to 90 days follow-up

  5. Motricity Index (MI)

    1. Change from Baseline: Motricity Index (MI). A test to assess motor impairment in stroke patients

    Measured: up to 21 days post baseline and up to 90 days follow-up

  6. Trunk Control Test (TCT)

    1. Change from Baseline: Trunk Control Test (TCT). A test to assess the ability to control the trunk after stroke.

    Measured: up to 21 days post baseline and up to 90 days follow-up

  7. Inter Hemispheric transmission Time (IHTT)

    1. Change from Baseline: Inter Hemispheric transmission Time (IHTT). Psychophysiological index of inter-hemispheric transmission time.

    Measured: up to 21 days post baseline and up to 90 days follow-up

  8. Level of Cognitive Functioning (LCF)

    1. Change from Baseline: Level of Cognitive Functioning (LCF). A test to assess general cognitive functioning.

    Measured: up to 21 days post baseline and up to 90 days follow-up

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Oct 2020
  2. Study start30 Mar 2021
  3. Primary completion30 Jan 2023 (estimated)
  4. Study completion30 Mar 2023 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
28 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04573413
Sponsor's protocol ID
SG-2018-12367527
Acronym
Smart trace
Status last verified
Feb 2022
First submitted
28 Sep 2020
Last updated
16 Feb 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Di Gregorio F, La Porta F, Lullini G, Casanova E, Petrone V, Simoncini L, Ferrucci E, Piperno R. Efficacy of Repetitive Transcranial Magnetic Stimulation Combined With Visual Scanning Treatment on Cognitive-Behavioral Symptoms of Unilateral Spatial Neglect in Patients With Traumatic Brain Injury: Study Protocol for a Randomized Controlled Trial. Front Neurol. 2021 Jul 14;12:702649. doi: 10.3389/fneur.2021.702649. eCollection 2021.

    PubMed 34335455

Questions about this trial

What is this clinical trial studying?

A study testing Inhibitory repetitive transcranial magnetic stimulation in people with Perceptual Disorders and Traumatic Brain Injury, run by Azienda Usl di Bologna at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 16 Feb 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Francesco Di Gregorio, PhD (3290762585, francesco.digregorio@ausl.bologna.it), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

visual-Attention Bias Index (vABI) (time frame: up to 21 days post baseline and up to 90 days follow-up). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04573413, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Feb 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in